CN101817769B - Carbamido peptide aminopeptidase N inhibitor and application thereof - Google Patents
Carbamido peptide aminopeptidase N inhibitor and application thereof Download PDFInfo
- Publication number
- CN101817769B CN101817769B CN 201010146905 CN201010146905A CN101817769B CN 101817769 B CN101817769 B CN 101817769B CN 201010146905 CN201010146905 CN 201010146905 CN 201010146905 A CN201010146905 A CN 201010146905A CN 101817769 B CN101817769 B CN 101817769B
- Authority
- CN
- China
- Prior art keywords
- hydroxyacetamide
- methyl
- tert
- butylureido
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 title abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 230000003287 optical effect Effects 0.000 claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- -1 nitro, cyano, guanidino, carboxyl Chemical group 0.000 claims description 55
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 33
- 229940024606 amino acid Drugs 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 108010043958 Peptoids Proteins 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- HZKBATKEYOCGAD-NSHDSACASA-N (2s)-2-(benzylcarbamoylamino)-n-hydroxy-3-methylbutanamide Chemical compound ONC(=O)[C@H](C(C)C)NC(=O)NCC1=CC=CC=C1 HZKBATKEYOCGAD-NSHDSACASA-N 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 239000012948 isocyanate Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- 150000004702 methyl esters Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012346 acetyl chloride Substances 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000009697 arginine Nutrition 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 235000013477 citrulline Nutrition 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 235000004554 glutamine Nutrition 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 235000014304 histidine Nutrition 0.000 claims description 5
- PHRZTXWNFAEVIA-UHFFFAOYSA-N hydroxylamine;potassium Chemical compound [K].ON PHRZTXWNFAEVIA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002591 hydroxyproline Drugs 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 235000013930 proline Nutrition 0.000 claims description 5
- 235000004400 serine Nutrition 0.000 claims description 5
- 235000008521 threonine Nutrition 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- LRCYAJZPDFSJPQ-UHFFFAOYSA-N 3-azaniumyl-2-phenylpropanoate Chemical compound NCC(C(O)=O)C1=CC=CC=C1 LRCYAJZPDFSJPQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- GKMHOQOLPKVIEQ-HNNXBMFYSA-N (2s)-2-(benzylcarbamoylamino)-n-hydroxy-3-phenylpropanamide Chemical compound C([C@@H](C(=O)NO)NC(=O)NCC=1C=CC=CC=1)C1=CC=CC=C1 GKMHOQOLPKVIEQ-HNNXBMFYSA-N 0.000 claims description 2
- CFTZXPAJFQAAJD-QMMMGPOBSA-N (2s)-2-(benzylcarbamoylamino)-n-hydroxypropanamide Chemical compound ONC(=O)[C@H](C)NC(=O)NCC1=CC=CC=C1 CFTZXPAJFQAAJD-QMMMGPOBSA-N 0.000 claims description 2
- GFSLJWUVFGHVNY-ZETCQYMHSA-N (2s)-2-(tert-butylcarbamoylamino)-n-hydroxy-3-methylbutanamide Chemical compound ONC(=O)[C@H](C(C)C)NC(=O)NC(C)(C)C GFSLJWUVFGHVNY-ZETCQYMHSA-N 0.000 claims description 2
- CWIRHWMITXKLHT-NSHDSACASA-N (2s)-2-(tert-butylcarbamoylamino)-n-hydroxy-3-phenylpropanamide Chemical compound CC(C)(C)NC(=O)N[C@H](C(=O)NO)CC1=CC=CC=C1 CWIRHWMITXKLHT-NSHDSACASA-N 0.000 claims description 2
- HMNXPCGYEKSOFV-ZETCQYMHSA-N (2s)-2-(tert-butylcarbamoylamino)-n-hydroxy-4-methylsulfanylbutanamide Chemical compound CSCC[C@@H](C(=O)NO)NC(=O)NC(C)(C)C HMNXPCGYEKSOFV-ZETCQYMHSA-N 0.000 claims description 2
- NOKJBVCPHGJAGW-YFKPBYRVSA-N (2s)-2-(tert-butylcarbamoylamino)-n-hydroxypropanamide Chemical compound ONC(=O)[C@H](C)NC(=O)NC(C)(C)C NOKJBVCPHGJAGW-YFKPBYRVSA-N 0.000 claims description 2
- FUFKPDYEOOZPGZ-VIFPVBQESA-N (2s)-n-hydroxy-2-(2-phenylethylcarbamoylamino)propanamide Chemical compound ONC(=O)[C@H](C)NC(=O)NCCC1=CC=CC=C1 FUFKPDYEOOZPGZ-VIFPVBQESA-N 0.000 claims description 2
- RQEMEJWGQJWBKF-LBPRGKRZSA-N (2s)-n-hydroxy-3-methyl-2-(2-phenylethylcarbamoylamino)butanamide Chemical compound ONC(=O)[C@H](C(C)C)NC(=O)NCCC1=CC=CC=C1 RQEMEJWGQJWBKF-LBPRGKRZSA-N 0.000 claims description 2
- RXQISZKOIVQTHA-INIZCTEOSA-N (2s)-n-hydroxy-3-phenyl-2-(2-phenylethylcarbamoylamino)propanamide Chemical compound C([C@@H](C(=O)NO)NC(=O)NCCC=1C=CC=CC=1)C1=CC=CC=C1 RXQISZKOIVQTHA-INIZCTEOSA-N 0.000 claims description 2
- YAVDAOYFBAYJLB-LBPRGKRZSA-N (2s)-n-hydroxy-4-methylsulfanyl-2-(2-phenylethylcarbamoylamino)butanamide Chemical compound CSCC[C@@H](C(=O)NO)NC(=O)NCCC1=CC=CC=C1 YAVDAOYFBAYJLB-LBPRGKRZSA-N 0.000 claims description 2
- UBELTUKKUSZEAK-UHFFFAOYSA-N 2-(benzylcarbamoylamino)-n-hydroxyacetamide Chemical compound ONC(=O)CNC(=O)NCC1=CC=CC=C1 UBELTUKKUSZEAK-UHFFFAOYSA-N 0.000 claims description 2
- UUCZOVXTPGVPPR-UHFFFAOYSA-N 2-(tert-butylcarbamoylamino)-n-hydroxyacetamide Chemical compound CC(C)(C)NC(=O)NCC(=O)NO UUCZOVXTPGVPPR-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- FANDEZCKSVQZMH-UHFFFAOYSA-N n-hydroxy-2-(2-phenylethylcarbamoylamino)acetamide Chemical compound ONC(=O)CNC(=O)NCCC1=CC=CC=C1 FANDEZCKSVQZMH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 102100022749 Aminopeptidase N Human genes 0.000 abstract description 31
- 108010049990 CD13 Antigens Proteins 0.000 abstract description 21
- 150000003839 salts Chemical class 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002159 abnormal effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000012453 solvate Substances 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 2
- 229940002612 prodrug Drugs 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 15
- 125000002950 monocyclic group Chemical group 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 7
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 6
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 108700027199 poly(N(epsilon)-benzyloxycarbonyl-L-lysine) Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229950009811 ubenimex Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001371 alpha-amino acids Chemical class 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 150000001576 beta-amino acids Chemical class 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- RPUSRLKKXPQSGP-UHFFFAOYSA-N methyl 3-phenylpropanoate Chemical compound COC(=O)CCC1=CC=CC=C1 RPUSRLKKXPQSGP-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004405 heteroalkoxy group Chemical group 0.000 description 3
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005241 heteroarylamino group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OJTJKAUNOLVMDX-LBPRGKRZSA-N (2s)-6-amino-2-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 OJTJKAUNOLVMDX-LBPRGKRZSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- MPHIJPXCDOWRGP-UHFFFAOYSA-N 2-(carboxymethylcarbamoylamino)-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound OC(=O)CNC(=O)NC(C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 MPHIJPXCDOWRGP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- AXZJHDNQDSVIDR-NSHDSACASA-N 4178-93-2 Chemical compound CC(C)C[C@H](N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 AXZJHDNQDSVIDR-NSHDSACASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710190444 Aminopeptidase M1 Proteins 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001232464 Delma Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000056826 Gluzincins Human genes 0.000 description 1
- 108091007247 Gluzincins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102400001355 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000218589 Streptomyces olivaceus Species 0.000 description 1
- 241000970901 Streptomyces olivoreticuli Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- HRSXWUSONDBHSP-UHFFFAOYSA-N benzyl hexanoate Chemical compound CCCCCC(=O)OCC1=CC=CC=C1 HRSXWUSONDBHSP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000679 brush border epithelial cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000005102 carbonylalkoxy group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a carbamido peptide aminopeptidase N inhibitor and application thereof. The invention provides the superactive peptide aminopeptidase N inhibitor, thereby being capable of curing the disease that the activity or the express of the aminopeptidase N is abnormal. Specifically, the invention relates to a peptide compound with the structures of general formulas (I), (II) or (III), and further relates to various optical isomers thereof, a pharmaceutically acceptable salt, a solvate and a prodrug. The invention further relates to a drug composite of the peptide compound which comprises the structures of the general formulas (I), (II) or (III) and use therefore for preparing the drug.
Description
Technical Field
The invention relates to a carbamido peptide aminopeptidase N inhibitor, a preparation method and application thereof, belonging to the technical field of chemistry.
Background
Aminopeptidase N (APN, CD13) is a family of type II membrane-bound glycoproteins with molecular weights of about 150Kd, belonging to the Gluzincins subfamily of the zinc ion-dependent metalloprotease and aminopeptidase M1 family, present in the cell membrane as homodimers and involved in the degradation of the N-terminal amino acids of the substrate. Aminopeptidase N is widely distributed in GM-SCF and myeloid cells at various stages of development; in non-blood cells, stromal cells distributed in hematopoietic organs, tumor vascular endothelial cells, various epithelial cells including renal proximal convoluted tubule epithelial cells, bile duct epithelial cells, small intestine brush border epithelial cells and the like; also distributed on the surface of fibroblasts, mesenchymal tumor cells, etc.; a small amount of soluble APN was also present in the serum. APN participates in physiological regulation of organisms and plays an important role in a plurality of physiological and pathological regulation networks such as blood cell differentiation, angiogenesis, cell proliferation and apoptosis, immunoregulation and the like. Research has shown that aminopeptidase N plays an important role in tumorigenesis, development, invasion and metastasis, apoptosis, tumor angiogenesis and viral infection.
1) Aminopeptidase N is expressed at high levels on the surface of tumor cells. The enzyme can degrade extracellular matrix, thereby promoting tumor cell invasion and metastasis. Extracellular matrix plays a very important role in maintaining the stability of cell junctions and intercellular signaling. Degradation of the extracellular matrix can also promote growth and proliferation of tumors by promoting the release of growth factors present therein (Sato Y, biol. pharm. Bull., 2004, 27 (6): 772-) 776; Saiki, I.; et al. int. J. cancer., 1993, 54, 137; Menrad A., Speicher D., Wacker J., et al. cancer Res., 1993, 53 (6): 1450-) 1455). 2) Aminopeptidase N can stimulate vascular endothelial cells to release tumor microvascular formation related factors and promote angiogenesis of tumor cells. The APN is highly expressed in endothelial cells and sub-endothelial cells of new vessels, and can facilitate the endothelial cells to invade other surrounding tissues. This is also the basis for angiogenesis, which is the first step in tumor growth and metastasis. 3) APN is expressed on the surfaces of granulocytes and lymphocytes in a large quantity, and is also involved in T lymphocyte-dependent inflammatory reaction; can also be expressed on the surface of antigen presenting cells to degrade immune active substances (such as interleukin-8); the recognition of T cells which are involved in antigen processing and cell surface major histocompatibility complex II (MHC-II) adhesion antigenic determinant dependence on the antigen reduces the recognition capability of the T cells to the antigen, simultaneously weakens the recognition and killing capability of macrophages and NK cells to tumor cells, reduces the immunity of the organism, thereby promoting the proliferation of the tumor cells and inhibiting the apoptosis of the tumor cells. 4) Aminopeptidase N acts as a receptor on the surface of human coronavirus HCoV-229E and transmissible gastroenteritis virus (TGEV) and infects the upper respiratory tract (e.g.: SARS) and acute enteritis, and its role is related to the activity of enzymes (Delmas, b., et al. nature, 1992, 357, 417; yeager, c.l.; et al. nature, 1992, 357, 420). APN is also involved in T lymphocyte-dependent inflammatory responses and in the entry of HIV viral particles into host cells. Studies have shown that aminopeptidase N activity in HIV-infected patients is much higher than in healthy volunteers (Shen W, Li B, et al. blood, 2000, 96(8), 2887; Shipp MA, et al. blood, 1993, 82(4), 1052). 5) Aminopeptidase N is involved in the degradation of the endogenous analgesic substances endorphins and enkephalins, causing the excessive release of substance P, resulting in pain. 6) Aminopeptidase N degrades angiotensin, and is involved in the regulation of body blood pressure (Mitsui, t.; et al biol pharm bull, 2004, 27, 768).
For over a decade, research and development of APN inhibitors has been extremely rapid, but to date there has been only one drug on the market, ubenimex. APN inhibitors act as inhibitors of peptidases, mostly peptides or peptide analogs, and are susceptible to degradation by enzymes in the body; in addition, because the control network for controlling tumor growth, proliferation and apoptosis is very large and complex, for example, the regulation network can complementarily promote tumor growth, proliferation and inhibit apoptosis through in vivo signal transduction of various growth factor receptor tyrosine kinases or through activation of integrin receptors, which is the reason why most of non-cytotoxic target type antitumor drugs including APN inhibitors are killed by gun in clinical stage. In addition, most of aminopeptidase N inhibitors currently under clinical or preclinical study are natural products, for example, Ubenimex (Ubenimex) is a dipeptide-like structure containing a beta-amino acid, and is currently used as an immunopotentiator for treating leukemia, is separated from a culture solution of Streptomyces olivaceus (Streptomyces olivoreticuli), and is expensive in total synthesis and limited in source.
The ureido peptide compound designed by the invention is found in the screening aiming at the aminopeptidase N activity, and the activity of several drug molecules is similar to or superior to that of the currently unique ubenimex on the market.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a carbamido peptide aminopeptidase N inhibitor, a preparation method and application thereof.
The technical scheme of the invention is as follows:
peptoid compounds having the general formula (I), (II) or (III), as well as optical isomers, diastereomers and racemic mixtures thereof, pharmaceutically acceptable salts, solvates or prodrugs thereof:
wherein,
R1is hydrogen, a substituent on the alpha carbon of various natural or unnatural amino acids, including: various α -amino acids such as glycine, alanine, valine, phenylalanine, isoleucine, leucine, methionine, lysine, ornithine, aspartic acid, asparagine, glutamic acid, glutamine, serine, threonine, histidine, tryptophan, arginine, cysteine, citrulline, proline, hydroxyproline, tyrosine, and the like; various beta-amino acids such as beta-aminopropionic acid, beta-aminophenylpropionic acid, and the like; gamma-amino acids such as gamma-aminobutyric acid and the like, D-amino acids such as glycine, alanine, valine, phenylalanine, isoleucine, leucine, methionine, lysine, ornithine, aspartic acid, asparagine, glutamic acid, glutamine, serine, threonine, histidine, tryptophan, arginine, cysteine, citrulline, proline, hydroxyproline, tyrosine and the like in D form; other amino acids such as various delta-amino acids, and the like.
R1' is hydrogen, a substituent on the alpha carbon of various natural or unnatural amino acids, including: various α -amino acids such as glycine, alanine, valine, phenylalanine, isoleucine, leucine, methionine, lysine, ornithine, aspartic acid, asparagine, glutamic acid, glutamine, serine, threonine, histidine, tryptophan, arginine, cysteine, citrulline, proline, hydroxyproline, tyrosine, and the like; various beta-amino acids such as beta-aminopropionic acid, beta-aminophenylpropionic acid, and the like; gamma-amino acids such as gamma-aminobutyric acid, etc., and D-amino acids such as D-form glycine, alanine, valine, phenylalanine, isoleucine, leucine, methionine, lysine, ornithine, aspartic acid, asparagine, glutamic acid, glutamine, serine, threonine, histidine, tryptophan, arginine, cysteine, citrulline, proline, hydroxyproline, etcAmino acids, amino acids; other amino acids such as various delta-amino acids, and the like.
R2Is hydrogen, C1-12 aliphatic alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; optionally substituted with one or more of the following groups: hydroxy, halogen, nitro, cyano, guanidino, carboxy, haloC 1-12 alkyl, C1-12 alkoxy, C1-12 alkyl, C1-12 cycloalkyl, aryl, heteroaryl, or arylC 1-12 alkyl;
x is hydroxamic acid, carboxyl; or C1-12 aliphatic alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, C1-12 aliphatic alkylamino, arylamino, arylalkylamino, heteroarylamino; optionally substituted with one or more of the following groups: hydroxy, halogen, nitro, cyano, guanidino, carboxy, haloC 1-12 alkyl, C1-12 alkoxy, C1-12 alkyl, C1-12 cycloalkyl, aryl, heteroaryl, arylC 1-12 alkyl;
y is hydrogen, aroyl, heteroaroyl, aryl C1-6 alkanoyl, heteroaryl C1-9 alkanoyl, C1-6 alkanoyl, arylsulfonyl, heterosulfonyl, aryl C1-6 alkylsulfonyl or heteroaryl C1-9 alkylsulfonyl; various protecting groups for protecting amino acid amino group, such as t-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethyloxycarbonyl, 2-biphenyl-2-propoxycarbonyl, phthalimido, p-toluenesulfonyl, trityl, formyl, acetyl or trifluoroacetyl group and the like.
The carbon represented by the above formula (I) or (II) has S configuration.
Preferably, the ureido peptoid compounds (I), (II) or (III) include the following compounds:
preferably, the ureido peptoid compound (I) is one of the following compounds:
1 a: 2- (3-tert-butylureido) -N-hydroxyacetamide,
2 a: (2S) -2-methyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
3 a: (2S) -2-isopropyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
4 a: (2S) -2- (2-methyl) -propyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
5 a: (2S) -2- (1-methyl) -propyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
6 a: (2S) -2-benzyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
7 a: (2S) -2- (methylthio) -ethyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
8 a: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-tert-butylureido) -N-hydroxyacetamide,
1 b: 2- (3-benzylureido) -N-hydroxyacetamide,
2 b: (2S) -2-methyl-2- (3-benzylureido) -N-hydroxyacetamide,
3 b: (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide,
4 b: (2S) -2- (2-methyl) -propyl-2- (3-benzylureido) -N-hydroxyacetamide,
5 b: (2S) -2- (1-methyl) -propyl-2- (3-benzylureido) -N-hydroxyacetamide,
6 b: (2S) -2-benzyl-2- (3-benzylureido) -N-hydroxyacetamide,
7 b: (2S) -2- (methylthio) -ethyl-2- (3-benzyl-tert-butylureido) -N-hydroxyacetamide,
8 b: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-benzyl-tert-butylureido) -N-hydroxyacetamide,
1 c: 2- (3-phenethylureido) -N-hydroxyacetamide,
2 c: (2S) -2-methyl-2- (3-phenethylureido) -N-hydroxyacetamide,
3 c: (2S) -2-isopropyl-2- (3-phenethylureido) -N-hydroxyacetamide,
4 c: (2S) -2- (2-methyl) -propyl-2- (3-phenethylureido) -N-hydroxyacetamide,
5 c: (2S) -2- (1-methyl) -propyl-2- (3-phenethylureido) -N-hydroxyacetamide,
6 c: (2S) -2-benzyl-2- (3-phenethylureido) -N-hydroxyacetamide,
7 c: (2S) -2- (methylthio) -ethyl-2- (3-phenethylureido) -N-hydroxyacetamide or
8 c: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-phenethylureido) -N-hydroxyacetamide.
Preferably, the ureido peptoid compound (II) is one of the following compounds:
1 f: 2- [3- (1-hydroxycarbamoyl-3-methyl-butyl) -ureido ] -4-methylpentanoic acid,
2 f: 2- [3- (1-hydroxycarbamoyl-3-methyl-butyl) -ureido ] -3-phenylpropionic acid,
3 f: 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -4-methylpentanoic acid,
4 f: 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionic acid,
1 g: 2- [3- (1-hydroxycarbamoyl-3-methyl-butyl) -ureido ] -4-methylpentanoic acid hydroxyamide,
2 g: 2- [3- (1-hydroxycarbamoyl-3-methyl-butyl) -ureido ] -3-phenylpropionic acid hydroxyamide,
3 g: 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -4-methylpentanoic acid hydroxyamide or
4 g: 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionic acid hydroxyamide.
Preferably, the ureido peptoid compound (III) is one of the following compounds:
1 d: 6-benzyloxycarbonylamino-2- (3-carboxymethylureido) -hexanoic acid,
2 d: (2S, 2' S) -6-benzyloxycarbonylamino-2- [3- (2-methyl) -carboxymethylureido ] -hexanoic acid,
3 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-ethyl) -ureido ] -hexanoic acid,
4 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-2-methylpropyl) -ureido ] -hexanoic acid,
5 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-3-methylbutyl) -ureido ] -hexanoic acid,
6 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-2-methylbutyl) -ureido ] -hexanoic acid,
7 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-2-benzyl) -ureido ] -hexanoic acid,
8 d: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (1-carboxy-3-methylthiopropyl) -ureido ] -hexanoic acid,
1 e: (2S, 1' S) -6-benzyloxycarbonylamino-2- [3- (5-benzyloxycarbonylamino-1-carboxy-pentyl) -ureido ] -hexanoic acid,
2 e: (3' S) - [ 5-Hydroxyaminocarbonyl-5- (3-Hydroxyaminocarbonylmethyl-ureido) -pentyl ] -carbamic acid benzyl ester,
3 e: (3 'S, 1' S) - { 5-Hydroxyaminocarbonyl-5- [3- (1-Hydroxyaminocarbonylethyl) -ureido ] -pentyl } -carbamic acid benzyl ester,
4 e: (3 'S, 1' S) - { 5-Hydroxyaminocarbonylmethyl-5- [3- (1-Hydroxyaminocarbonyl-2-methyl) -propylureido ] -pentyl } -carbamic acid benzyl ester,
5 e: (3 'S, 1' S) - { 5-Hydroxyaminocarbonylmethyl-5- [3- (1-Hydroxyaminocarbonyl-3-methyl) -butylureido ] -pentyl } -carbamic acid benzyl ester,
6 e: (3 'S, 1' S) - { 5-Hydroxyaminocarbonylmethyl-5- [3- (1-Hydroxyaminocarbonyl-2-phenethylureido ] -pentyl } -carbamic acid benzyl ester,
7 e: (3 'S, 1' S) - { 5-Hydroxyaminocarbonylmethyl-5- [3- (1-Hydroxyaminocarbonyl-3-methylsulfanyl) -propylureido ] -pentyl } -carbamic acid benzyl ester,
8 e: (3 'S, 1' S) - {5- [3- (5-benzyloxycarbonylamino-1-hydroxyaminocarbonyl-pentyl) -ureido ] -5-hydroxyaminocarbonyl-pentyl } -carbamic acid benzyl ester,
1 h: (2S) -6-benzyloxycarbonyl-2- (3-methoxycarbonylmethyl-ureido) hexanoic acid methyl ester,
2 h: (2S, 2' S) -6-benzyloxycarbonyl 2- [3-2- (methoxycarbonylethyl) -ureido ] hexanoic acid methyl ester,
3 h: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-methoxycarbonyl-2-methylpropyl) -ureido ] hexanoic acid methyl ester,
4 h: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-methoxycarbonyl-3-methylbutyl) -ureido ] hexanoic acid methyl ester,
5 h: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-methoxycarbonyl-2-methylbutyl) -ureido ] hexanoic acid methyl ester,
6 h: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-methoxycarbonyl-2-phenylethyl) -ureido ] hexanoic acid methyl ester,
7 h: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-methoxycarbonyl-3-methylthiopropyl) -ureido ] hexanoic acid methyl ester,
1 i: (2S) -6-benzyloxycarbonyl-2- (3-benzyloxycarbonylmethyl-ureido) hexanoic acid benzyl ester,
2 i: (2S, 2' S) -6-benzyloxycarbonyl 2- [3-2- (benzyloxycarbonylethyl) -ureido ] hexanoic acid benzyl ester,
3 i: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-benzyloxycarbonyl-2-methylpropyl) -ureido ] hexanoic acid benzyl ester,
4 i: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-benzyloxycarbonyl-3-methylbutyl) -ureido ] hexanoic acid benzyl ester,
5 i: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-benzyloxycarbonyl-2-methylbutyl) -ureido ] hexanoic acid benzyl ester,
6 i: (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-benzyloxycarbonyl-2-phenylethyl) -ureido ] hexanoic acid benzyl ester or
7 i: benzyl (2S, 1' S) -6-benzyloxycarbonyl-2- [3- (1-benzyloxycarbonyl-3-methylthiopropyl) -ureido ] hexanoate.
Among the above compounds, the most preferred are: 4b, 5b, 6b, 7b, 4c, 6c, 4d, 4 e.
In addition, the present invention also includes a pharmaceutical composition suitable for oral administration to a mammal comprising a peptoid compound of the above general formula (I), (II) or (III) and a pharmaceutically acceptable carrier, optionally comprising one or more pharmaceutically acceptable excipients.
In addition, the present invention also includes a pharmaceutical composition suitable for parenteral administration to a mammal comprising a peptoid compound of the above general formula (I), (II) or (III) and a pharmaceutically acceptable carrier, optionally comprising one or more pharmaceutically acceptable excipients.
The use of these peptoid compounds in medicaments for the prevention or treatment of mammalian diseases associated with abnormal aminopeptidase N activity or expression. The related mammal diseases with abnormal aminopeptidase N activity or expression comprise: inflammation, cancer, multiple sclerosis, various tissue ulcers or ulcerative conditions, periodontal disease, epidermolysis bullosa, leukemia, and the like. Therefore, the invention also relates to a pharmaceutical composition containing the compound with the structure (I), (II) or (III).
Detailed Description
Definitions and terms used
The terms and definitions used herein have the following meanings:
"substituents on the alpha carbon of various natural or unnatural amino acids": refers to 20 kinds of natural amino acids, non-natural alpha-amino acids, beta-amino acids, gamma-amino acids, delta-amino acids, D-amino acids, etc., and their derivatives, preferably natural alpha-amino acids, such as phenylalanine, isoleucine, leucine, methionine.
"halo", or "halogen" includes fluorine, chlorine, bromine or iodine.
"cycloalkyl" is a substituted or unsubstituted, saturated or unsaturated, cyclic alkyl group containing carbon atoms and/or one or more heteroatoms. The rings may be monocyclic or fused, bridged or spiro ring systems. Monocyclic rings usually have 3 to 9 atoms, preferably 4 to 7 atoms, and polycyclic rings have 7 to 17 atoms, preferably 7 to 13 atoms.
"heteroalkyl" refers to a saturated or unsaturated chain containing carbon atoms and at least one heteroatom, any one of which is not adjacent. The heteroalkyl group contains 2 to 15 atoms (carbon atoms), preferably 2 to 10 atoms. Heteroalkyl groups may be straight or branched, substituted or unsubstituted.
"aryl" means an aromatic carbocyclic group, preferably an aromatic ring containing 6 to 10 carbon atoms.
"heteroaryl" is an aromatic heterocycle, which may be a monocyclic or bicyclic group.
"cycloalkoxy" is a substituted or unsubstituted, saturated or unsaturated, cyclic alkoxy group containing carbon atoms and/or one or more heteroatoms. The rings may be monocyclic or fused, bridged or spiro ring systems. Monocyclic rings usually have 3 to 9 atoms, preferably 4 to 7 atoms, and polycyclic rings have 7 to 17 atoms, preferably 7 to 13 atoms.
"cycloalkylamino" is a substituted or unsubstituted, saturated or unsaturated, cyclic alkylamino radical containing carbon atoms and/or one or more heteroatoms. The rings may be monocyclic or fused, bridged or spiro ring systems. Monocyclic rings usually have 3 to 9 atoms, preferably 4 to 7 atoms, and polycyclic rings have 7 to 17 atoms, preferably 7 to 13 atoms.
"Heteroalkoxy" refers to a saturated or unsaturated chain containing carbon atoms and at least one heteroatom, any one of which is not adjacent. The heteroalkoxy group contains 2 to 15 atoms (carbon atoms), preferably 2 to 10 atoms. The heteroalkoxy group can be straight or branched, substituted or unsubstituted.
"Heteroalkylamino" refers to a saturated or unsaturated chain containing carbon atoms and at least one heteroatom, any one of which is not adjacent. The heteroalkylamine group contains 2 to 15 atoms (carbon atoms), preferably 2 to 10 atoms. The heteroalkylamine group can be straight-chain or branched, substituted or unsubstituted.
"aryloxy" refers to an aromatic carbocyclic oxy group, the preferred aromatic ring containing 6 to 10 carbon atoms.
"arylamino" refers to an aromatic carbocyclic amine group, the preferred aromatic ring containing 6 to 10 carbon atoms.
A "heteroaryloxy" group is an aromatic heterocycloxy group, which may be a monocyclic or bicyclic group.
A "heteroarylamine" is an aromatic heterocyclic amine group that may be a monocyclic or bicyclic group.
"aroyl" refers to a group having a carbonyl group attached to the end of an aromatic carbocyclic ring. Preferred aromatic rings contain 6 to 10 carbon atoms.
"Cycloalkanoyl" is a substituted or unsubstituted, saturated or unsaturated cyclic terminal carbonyl-containing group containing carbon atoms and/or one or more heteroatoms. The rings may be monocyclic or fused, bridged or spiro ring systems. Monocyclic rings usually have 3 to 9 atoms, preferably 4 to 7 atoms, and polycyclic rings have 7 to 17 atoms, preferably 7 to 13 atoms.
"Heteroaroyl" is a group having a carbonyl group attached to the end of an aromatic heterocycle, and may be a monocyclic or bicyclic group. Preferred heteroaryl groups include, for example, thienyl, furyl, pyrrolyl, pyridyl, pyrazinyl, thiazolyl, pyrimidinyl, quinolinyl, and tetrazolyl, benzothiazolyl, benzofuryl, indolyl, and the like.
"heteroalkyl" refers to a saturated or unsaturated chain containing carbon atoms and at least one heteroatom, any one of which is not adjacent. The heteroalkyl group contains 2 to 15 atoms (carbon atoms), preferably 2 to 10 atoms. Heteroalkyl groups may be straight or branched, substituted or unsubstituted.
"aryl" refers to an aromatic carbocyclic group. Preferred aromatic rings contain 6 to 10 carbon atoms.
"cycloalkyl" is a substituted or unsubstituted, saturated or unsaturated cyclic group containing carbon atoms and/or one or more heteroatoms. The rings may be monocyclic or fused, bridged or spiro ring systems. Monocyclic rings usually have 3 to 9 atoms, preferably 4 to 7 atoms, and polycyclic rings have 7 to 17 atoms, preferably 7 to 13 atoms.
By "pharmaceutically acceptable salt" is meant a therapeutically effective and non-toxic salt form of a compound of formula (I), (II) or (III). Which can form a cationic salt from any basic group, such as an amino group. Many such salts are known in the art. A cationic salt formed on any acidic group (e.g., a carboxyl group), or an anionic salt formed on any basic group (e.g., an amino group). Many of these salts are known in the art, such as cationic salts including salts of alkali metals (e.g., sodium and potassium) and alkaline earth metals (e.g., magnesium and calcium) and organic salts (e.g., amine salts). These salts are well known to the skilled artisan and the skilled artisan can prepare any of the salts provided by the knowledge in the art. In addition, the skilled artisan may select one salt and select another salt depending on solubility, stability, ease of formulation, etc. The determination and optimization of these salts is within the experience of the skilled artisan.
A "solvate" is a complex of a solute (e.g., an aminopeptidase N inhibitor) and a solvent (e.g., water). See J.Honig et al, The Van Nostrand and chemistry's Dictionary, p.650 (1953). Pharmaceutically acceptable solvents useful in the present invention include those that do not interfere with the biological activity of the aminopeptidase N inhibitor (e.g., water, ethanol, acetic acid, N-dimethylformamide, dimethylsulfoxide, and solvents known or readily determined by those skilled in the art).
The terms "optical isomers", "enantiomers", "diastereomers", "racemates" and the like, as used herein, define all possible stereoisomeric forms of the compounds of the present invention or physiological derivatives thereof. Unless otherwise indicated, the chemical designation of the compounds of the invention includes mixtures of all possible stereochemical forms, which mixtures comprise all diastereomers and enantiomers of the basic structural molecule, as well as the substantially pure individual isomeric forms of the compounds of the invention, i.e. containing less than 10%, preferably less than 5%, in particular less than 2%, most preferably less than 1% of other isomers. Various stereoisomeric forms of the peptoid compounds of the present invention are expressly included within the scope of the present invention.
The peptoid compounds of formula (I), (II) or (III) may also exist in other protected forms or derivatives, which are obvious to those skilled in the art and are intended to be included within the scope of the present invention.
The substituents described above may themselves be substituted by one or more substituents. Such substituents include those listed in C.Hansch and A.Leo, scientific Constants for Correlation Analysis in Chemistry and Biology (1979). Preferred substituents include, for example, alkyl, alkenyl, alkoxy, hydroxy, oxy, nitro, amino, aminoalkyl (e.g., aminomethyl, and the like), cyano, halo, carboxy, carbonylalkoxy (e.g., carbonylathoxy, and the like), thio, aryl, cycloalkyl, heteroaryl, heterocycloalkyl (e.g., piperidinyl, morpholinyl, pyrrolyl, and the like), imino, hydroxyalkyl, aryloxy, arylalkyl, and combinations thereof.
The preparation method of the compound comprises the following reaction steps and the reaction formula:
the preparation of compound (I) is as follows:
using optical amino acid as a raw material, sequentially protecting carboxyl through esterification, carrying out condensation connection on corresponding amine through triphosgene, and carrying out corresponding reaction on methyl ester to obtain a target compound; or the corresponding amine is converted into isocyanate by triphosgene, and then condensed with methyl ester of optical amino acid, and then the methyl ester is subjected to corresponding reaction to obtain the target compound.
The synthetic route is as follows:
the preparation method of the compound (II) is as follows:
the method comprises the steps of using optical amino acid as a raw material, sequentially protecting carboxyl groups through esterification, carrying out condensation through triphosgene, connecting another optical amino acid with the carboxyl groups protected through esterification, removing protecting groups to be removed, and carrying out corresponding reaction on methyl ester to obtain a target compound.
The synthetic route is as follows:
the preparation method of the compound (III) is as follows:
the target compound is obtained by using benzyloxycarbonyl lysine as a raw material, sequentially protecting amino with tert-butoxycarbonyl, condensing with various alcohols, phenols and amines, removing tert-butoxycarbonyl, condensing with triphosgene to connect related groups, removing benzyloxycarbonyl, or continuing to condense with corresponding acyl chloride or anhydride, or adding other amino protecting groups.
The synthetic route is as follows:
r is as defined above1、R1’、R2X, Y as defined above for peptoid compounds of general formula (I), (II) or (III);
reagents and reaction conditions in the above reaction formula: (a) acetyl chloride, anhydrous methanol, reflux, (b) triphosgene, saturated aqueous sodium bicarbonate, dichloromethane, 0 ℃, (c) as used, the various aforementioned amines, triethylamine, dichloromethane, (d) potassium hydroxylamine, anhydrous methanol, 25 ℃, (e) as used, triphosgene, toluene, reflux, (f) as used, the various aforementioned amino acid methyl ester hydrochlorides, triethylamine, dichloromethane, (g) as used, the various aforementioned amino acid methyl ester hydrochlorides, triethylamine, dichloromethane, (h) as used, p-toluenesulfonic acid, benzyl alcohol, 90 ℃, (i) as used, the various aforementioned amino acid methyl ester hydrochlorides, triethylamine, dichloromethane, (j) palladium/carbon, hydrogen, anhydrous methanol, 30 ℃, (k) as used, the various aforementioned amino acid methyl ester hydrochlorides, triethylamine, dichloromethane, (l) preparation of carboxylic acids: 1mol/L sodium hydroxide and methanol at 25 ℃; preparation of hydroxamic acid: potassium hydroxylamine, anhydrous methanol, 25 ℃, (m) (Boc)2O, aqueous sodium hydroxide solution, tetrahydrofuran, room temperature, (n) as used, the various alcohols, phenols or amines mentioned above, EDCI, HOBt, dichloromethane, room temperature, (O) saturated solution of HCl in ethyl acetate, room temperature, (p) triethylamine, dichloromethane, room temperature, (q) palladium on carbon, hydrogen, anhydrous methanol, 30 ℃, (r) as used, the acid chlorides or acid anhydrides corresponding to the various acyl groups mentioned above.
The specific procedures for the compounds are described in detail in the examples.
The skilled person can vary the above steps to increase the yield, and can determine the synthetic route according to the basic knowledge in the art, such as choice of reactants, solvents and temperature, and can increase the yield by using various conventional protecting groups to avoid side reactions. These conventional protection methods can be found, for example, in T.Greene, Protecting Groups in organic Synthesis.
Obviously, the above-mentioned route is a stereoselective synthesis, and an optically active peptoid compound can be prepared by the above-mentioned route. For example, various amino acids as starting materials are replaced with optical isomers thereof (D configuration). Various other isomers of such ureido-like peptide derivatives are readily available to those skilled in the art and may be purified by conventional separation means, such as chiral salts or chiral chromatography columns, and the like.
The assay for aminopeptidase N inhibitory activity is described in Lejczak, B et al Biochemistry, 1989, 28, 3549. The substrate L-leucyl-p-nitroaniline is degraded by aminopeptidase N to produce p-nitroaniline having an absorption at 405nm, and the concentration of p-nitroaniline is positively correlated with the magnitude of the enzyme activity. The content of p-nitroaniline is determined by detecting the absorbance at 405nm, so that the activity of aminopeptidase is determined, and the degree of inhibition of the inhibitor on the enzyme activity is indirectly reflected.
The in vitro enzyme inhibition test of the peptide-like compound with the general formula (I), (II) or (III) proves that the peptide-like compound is a carbamido peptide aminopeptidase N inhibitor. The ureido peptoids of the invention are spatially matched to the active site of aminopeptidase N and thus exhibit high aprotinin activity in vitro.
Ubenimex, an aminopeptidase N inhibitor, has been on the market for many years in clinical use for the treatment of leukemia and can be used as an immunomodulator. The compound of the invention is used as the application of the carbamido peptide aminopeptidase N inhibitor. Has wide application prospect in preparing medicaments for preventing or treating mammal diseases related to the abnormal expression of the aminopeptidase N activity. According to the prior art, the mammalian diseases associated with the abnormal expression of aminopeptidase N activity include: inflammation, cancer, multiple sclerosis, various tissue ulcers or ulcerative conditions, periodontal disease, epidermolysis bullosa and leukemia.
Pharmaceutical compositions containing the compounds of the invention:
the partial derivatives of the invention may be present in free form or in salt form. Pharmaceutically acceptable salts of many compound types and methods for their preparation are known to those skilled in the art. Pharmaceutically acceptable salts include conventional non-toxic salts, including salts of such compounds formed from acids and inorganic or organic bases.
The compounds of the present invention may form hydrates or solvates. The person skilled in the art is aware of methods for forming hydrates when compounds are lyophilized together with water or solvates when concentrated in solution with suitable organic solvents.
The invention encompasses pharmaceutical compositions comprising a therapeutic amount of a compound of the invention, and one or more pharmaceutically acceptable carriers and/or excipients. Carriers include, for example, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof, as discussed in more detail below. The composition may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired. The composition can be in the form of a liquid, suspension, emulsion, tablet, pill, capsule, sustained release formulation or powder. The composition can be formulated into suppository with conventional binder and carrier such as triglyceride. Oral formulations may include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose and magnesium carbonate, and the like. Depending on the desired formulation, the formulation may be designed to mix, granulate and compress or dissolve the ingredients. In another approach, the composition may be formulated as nanoparticles.
The pharmaceutical carrier used may be, for example, a solid or a liquid.
Typical solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. The solid carrier may comprise one or more substances which may act simultaneously as flavouring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrants; it may also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with the carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Powders and tablets preferably contain up to 99% active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
Typical liquid carriers include syrup, peanut oil, olive oil, water, and the like. Liquid carriers are used to prepare solutions, suspensions, emulsions, syrups, tinctures and sealed compositions. The active ingredient may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or a pharmaceutically acceptable oil or fat. The liquid carrier may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, pigments, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (containing in part additives as described above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). The carrier for parenteral administration may also be an oil or fat such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are sterile liquid compositions for parenteral administration. The liquid carrier for the pressurized composition may be a halogenated hydrocarbon or other pharmaceutically acceptable propellant. Sterile solutions or suspension solutions liquid pharmaceutical compositions may be used, for example, for intravenous, intramuscular, intraperitoneal or subcutaneous injection. The injection can be performed by single push or gradual injection, and is infused into channels and collaterals for 30 minutes. The compounds may also be administered orally in the form of liquid or solid compositions.
The carrier or excipient may comprise a time delay material known in the art, such as glyceryl monostearate or glyceryl distearate, and may also comprise a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate, or the like. When the formulation is intended for oral administration, it is recognized that 0.01% tween 80 in phostapg-50 (phosphoipid and 1, 2-propanediol concentrate, a. nattermann & cie. gmbh) is used in the formulation of acceptable oral formulations of other compounds, and may be adapted to the formulation of various compounds of the invention.
A wide variety of pharmaceutical forms can be used in administering the compounds of the present invention. If a solid carrier is used, the preparation may be in the form of a tablet, powder or pellet placed in a hard gelatin capsule or in the form of a lozenge or troche. The amount of solid carrier varies widely, but is preferably from about 25mg to about 1.0 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or in a nonaqueous liquid suspension.
To obtain a stable water-soluble dosage form, the compound or a pharmaceutically acceptable salt thereof may be dissolved in an aqueous solution of an organic or inorganic base. If a soluble form is not obtained, the compound may be dissolved in a suitable co-solvent or combination thereof. Examples of such suitable co-solvents include, but are not limited to, ethanol at a concentration ranging from 0 to 60% by volume of the total volume, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerol, polyoxyethylene fatty acid esters, fatty alcohols or glycerol hydroxy fatty acid esters, and the like.
Various delivery systems are known and may be used for the administration of compounds or other various formulations including tablets, capsules, injectable solutions, capsules in liposomes, microparticles, microcapsules, and the like. Methods of introduction include, but are not limited to, cutaneous, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, pulmonary, epidural, ocular and (generally preferred) oral routes. The compounds may be administered by any convenient or other suitable route, for example by infusion or bolus injection, by absorption through epithelial or mucosal lines (e.g., oral mucosa, rectal and intestinal mucosa, etc.) or by drug-loaded stents and may be administered together with other biologically active agents. Can be administered systemically or locally. For use in the treatment or prevention of a hetero-, bronchial or pulmonary disorder, the preferred route of administration is oral, nasal or bronchial aerosol or nebulizer.
The design of the present invention involving compounds of the general formula (I), (II) or (III) as described above employs peptoid and isostere design strategies. Peptoid and isostere strategies have been widely applied to the field of design and development of antiviral and antitumor drugs, the structure of the peptoid and isostere strategies is similar to that of a peptide composed of natural or unnatural amino acids and non-peptide groups, but the overall conformation of the peptoid and isostere strategies is different from that of a natural polypeptide substance, on one hand, the peptoid has the intrinsic activity of a substrate, the activity of an enzyme can be inhibited by recognizing the active center of the enzyme, and meanwhile, the selectivity and the efficiency of a target site are improved; in addition, the peptoid and the natural peptide have structural difference, so that the peptoid is not easily degraded by peptidase, the biological stability and the utilization rate are improved, and the compound has long action time.
Specifically, the method takes optical purity amino acid as a raw material, selectively protects carboxyl, and synthesizes key intermediates through steps of substitution, condensation, deprotection and the like, and aims to enhance the affinity and metabolic stability of the compound with enzyme or receptor.
The aminopeptidase N inhibitor with a brand-new mother nucleus designed and synthesized by the invention has no cytotoxic activity but shows obvious in-vitro enzyme inhibitory activity as shown by in-vitro experiments, and is expected to become a non-cytotoxic anticancer candidate drug.
Detailed Description
The present invention will be further described with reference to the following examples, but is not limited thereto.
EXAMPLE 1 Synthesis of Compound (I) of the present invention
1. Taking (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide (3b) as an example:
1) preparation of benzyl isocyanate (1)
A solution of 1.16g of benzylamine in 20mL of toluene was added dropwise to 80mL of a toluene solution of 2.22g of triphosgene at room temperature, and the reaction mixture was refluxed for 4 hours, and then toluene was evaporated to dryness to obtain benzyl isocyanate (1) as a yellow oily product, which was used in the next step without further purification.
2) Preparation of methyl 2- (3-benzylureido) -2-isopropylacetate (2)
After the dichloromethane solution of benzyl isocyanate (1) was dropped into the dichloromethane solution containing 2.51g L-valine methyl ester hydrochloride and 2.12g of triethylamine in ice bath, the reaction solution was stirred at room temperature, after 1 hour, dichloromethane was evaporated to dryness, the residue was dissolved in ethyl acetate, and then the mixture was washed with 1N hydrochloric acid and saturated brine, and the organic phase was dried over magnesium sulfate. Methyl 2- (3-benzylureido) -2-isopropylacetate (2) was obtained as a yellow oil which was used in the next step without further purification.
3)NH2Preparation of OK
Dropping 140mL of saturated anhydrous methanol solution of KOH into 240mL of anhydrous methanol solution containing 46.7g (670mmol) of hydroxylamine hydrochloride, controlling the internal temperature to be lower than 40 ℃, cooling the reaction solution after dropping, filtering off white KCl precipitate, and hermetically storing the obtained filtrate for later use.
4) Preparation of (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide (3b)
Methyl 2- (3-benzylureido) -2-isopropylacetate (2) was added to the above 30mL of hydroxylamine potassium in methanol, stirred at room temperature and monitored by TLC for progress. After completion of the reaction, methanol was distilled off under reduced pressure, the residue was dissolved in 1N hydrochloric acid, pH was adjusted to 1-2, ethyl acetate was added for extraction, the organic phase was washed with saturated brine and dried. Crude product (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide (3b) was obtained as an off-white solid, which was separated by column chromatography (petroleum ether: ethyl acetate: 2: 1) to obtain 2.47g of (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide (3b) as a white solid in 68% overall yield. mp 180-. ESI-MS m/z: 265.3[ M + H]+。1H-NMR(300MHz,DMSO-d6):δ10.61(s,1H),δ8.80(s,1H),δ7.33-7.19(m,5H),δ6.50(t,1H,J=6.0Hz),δ6.16(d,1H,J=9.3Hz),δ4.20(d,2H,J=6.0Hz),δ3.87(dd,1H,J=7.2Hz,9.3Hz),δ1.85-1.74(m,1H),δ0.85(d,6H,6.9Hz)。
Example 2 Synthesis of Compound (III) of the present invention
Using (2S) -6-benzyloxycarbonyl-2- (3-methoxycarbonylmethyl-ureido) hexanoic acid methyl ester (1h) as an example:
1) preparation of N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride (3)
Slowly dropwise adding 50mL of anhydrous methanol into 2.35g of acetyl chloride in an ice bath, stirring at room temperature for half an hour after dropwise adding, then adding 2.80g N6-benzyloxycarbonyl-L-lysine once, then slowly heating the reaction mixture to reflux, and evaporating the methanol after 1 hour to obtain a white solid compound N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride (3), wherein the white solid compound can be directly used for the next reaction without further purification.
2) Preparation of N6-benzyloxycarbonyl-L-lysine methyl ester-1-isocyanate (4)
N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride (3) obtained in the above step 1) was added to 40mL of a saturated sodium bicarbonate solution and 40mL of dichloromethane, and 1.00g of triphosgene was added at a time with stirring in an ice bath. Stirring vigorously in ice bath for 15min, separating, extracting water layer with dichloromethane three times, combining organic layers, and drying. The solvent was evaporated to dryness to give compound N6-benzyloxycarbonyl-L-lysine methyl ester-1-isocyanate (4), which was used directly in the next reaction without purification.
3) Preparation of Glycine methyl ester hydrochloride (5)
Slowly dropwise adding 50mL of anhydrous methanol into 2.35g of acetyl chloride in an ice bath, stirring at room temperature for half an hour after dropwise adding, then adding 0.75g of glycine once, then slowly heating the reaction mixture to reflux, and after 1 hour, evaporating the methanol to dryness to obtain a white solid compound glycine methyl ester hydrochloride (5), wherein the white solid compound glycine methyl ester hydrochloride can be directly used for the next reaction without further purification.
4) Preparation of (2S) -6-benzyloxycarbonyl-2- (3-methoxycarbonylmethyl-ureido) hexanoic acid methyl ester (1h)
Glycine obtained in the above step 3)Acid methyl ester hydrochloride (5) and 1.01g triethylamine were stirred in 20mL dichloromethane, 10mLN 6-carbobenzoxy-L-lysine methyl ester-1-isocyanate (4) solution in dichloromethane was added dropwise in ice bath, after the addition was completed, stirring was performed at room temperature for one hour, dichloromethane was evaporated to dryness, the residue was dissolved in ethyl acetate, washed with 1N hydrochloric acid and saturated brine, and then the organic phase was dried. The solvent was evaporated to dryness to give crude (2S) -6-benzyloxycarbonyl-2- (3-methoxycarbonylmethyl-ureido) methyl hexanoate (1h) as a yellow oil, which was separated by column chromatography (petroleum ether: ethyl acetate: 1: 4) to give 1.48g of methyl (2S) -6-benzyloxycarbonyl-2- (3-methoxycarbonylmethyl-ureido) hexanoate as a white solid (1h), in 39% overall yield. ESI-MS m/z: 410.2[ M + H]+。1H-NMR(600MHz,CDCl3):δ7.36-7.26(m,5H),δ5.13-5.04(m,3H),δ4.48-4.44(m,2H),δ3.73(s,3H),δ3.71(s,3H),δ3.21-3.17(m,2H),δ1.81-1.35(m,6H).
EXAMPLE 3 Synthesis of Compound (II) of the present invention
Taking 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionic acid hydroxyamide (4g) as an example:
1) preparation of phenylalanine methyl ester hydrochloride (6)
Slowly dropwise adding 100mL of anhydrous methanol into 4.24g of acetyl chloride in an ice bath, stirring at room temperature for half an hour after dropwise adding, then adding 2.98g of phenylalanine once, then slowly heating the reaction mixture to reflux, and evaporating the methanol after 1 hour to obtain a white solid compound, namely phenylalanine methyl ester hydrochloride (6), wherein the white solid compound can be directly used for the next reaction without further purification.
2) Preparation of phenylalanine methyl ester-1-isocyanate (7)
1.90g of phenylalanine methyl ester hydrochloride (6) obtained in the above step 1) was added to 40mL of a saturated sodium bicarbonate solution and 40mL of dichloromethane, and 1.00g of triphosgene was added at a time with stirring in an ice bath. Stirring vigorously in ice bath for 15min, separating, extracting water layer with dichloromethane three times, combining organic layers, and drying. The solvent is evaporated to dryness to obtain the compound phenylalanine methyl ester-1-isocyanate (7), which can be directly used for the next reaction without purification.
3) Preparation of methyl 2- [3-1- (methoxycarbonyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionate (8)
Stirring 1.90g of phenylalanine methyl ester hydrochloride (6) obtained in the step 1) and 1.01g of triethylamine in 20mL of dichloromethane, dropwise adding a dichloromethane solution of phenylalanine methyl ester-1-isocyanate (7) in ice bath, stirring at room temperature for one hour after the dropwise adding is finished, evaporating dichloromethane, dissolving the residue in ethyl acetate, washing with 1N hydrochloric acid and saturated saline solution, and drying the organic phase. The solvent was evaporated to dryness to give a crude 2- [3-1- (methoxycarbonyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionic acid methyl ester (8) as a yellow oil, which was used directly in the next reaction without further purification.
4) Preparation of 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido ] -3-phenylpropionic acid hydroxyamide (4g)
Reacting 2- [3-1- (methoxycarbonyl-2-phenyl-ethyl) -ureido]Methyl-3-phenylpropionate (8) was added to the above 30mL of hydroxylamine potassium in methanol, stirred at room temperature and monitored by TLC for progress. After the reaction was completed, methanol was distilled off under reduced pressure, the residue was dissolved in 1N hydrochloric acid, pH was adjusted to 1-2, a white precipitate was precipitated, and the precipitate was washed with ethyl acetate and then dried in vacuum. To give the product 2- [3- (1-hydroxycarbamoyl-2-phenyl-ethyl) -ureido]-3-phenylpropionic acid hydroxyamide (4g) was 1.89g of white solid, 54% overall yield. ESI-MS m/z: 386.2[ M + H]+。1H-NMR(300MHz,DMSO-d6):δ10.71(s,1H),δ10.56(s,1H),δ8.93(s,1H),δ8.81(s,1H),δ7.32-7.07(m,10H),δ6.38-6.35(m,2H),δ4.05-4.18(m,2H),δ2.84-2.51(m,4H).
EXAMPLE 4 Activity test of the object Compound for inhibition of aminopeptidase N (In vitro)
The test principle and the detailed test steps are referred to CN 1974554A cyclic imide peptide metalloprotease inhibitor and the application thereof, and the test results are shown in Table 1.
TABLE 1 results of in vitro enzyme inhibition assay
aNA=not available
The test data in the table show that the inhibition activity of the compounds 4b, 5b, 6b, 7b, 4c, 6c, 4d and 4e on the aminopeptidase N is better than that of a positive control drug ubenimex, and the compound has good development prospect.
Claims (4)
1. A compound of general formula (I):
wherein,
R1is hydrogen, a substituent on the alpha carbon of various natural or unnatural amino acids: alanine, valine, phenylalanine, isoleucine, leucine, methionine, lysine, ornithine, aspartic acidAsparagine, glutamic acid, glutamine, serine, threonine, histidine, tryptophan, arginine, cysteine, citrulline, proline, hydroxyproline, tyrosine; beta-aminopropionic acid, beta-aminophenylpropionic acid; gamma-aminobutyric acid;
R2is hydrogen, C1-12 fatty alkanyl, optionally substituted with one or more of the following: hydroxyl, halogen, nitro, cyano, guanidino, carboxyl.
2. A compound characterized by being one of the following:
1 a: 2- (3-tert-butylureido) -N-hydroxyacetamide,
2 a: (2S) -2-methyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
3 a: (2S) -2-isopropyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
4 a: (2S) -2- (2-methyl) -propyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
5 a: (2S) -2- (1-methyl) -propyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
6 a: (2S) -2-benzyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
7 a: (2S) -2- (methylthio) -ethyl-2- (3-tert-butylureido) -N-hydroxyacetamide,
8 a: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-tert-butylureido) -N-hydroxyacetamide,
1 b: 2- (3-benzylureido) -N-hydroxyacetamide,
2 b: (2S) -2-methyl-2- (3-benzylureido) -N-hydroxyacetamide,
3 b: (2S) -2-isopropyl-2- (3-benzylureido) -N-hydroxyacetamide,
4 b: (2S) -2- (2-methyl) -propyl-2- (3-benzylureido) -N-hydroxyacetamide,
5 b: (2S) -2- (1-methyl) -propyl-2- (3-benzylureido) -N-hydroxyacetamide,
6 b: (2S) -2-benzyl-2- (3-benzylureido) -N-hydroxyacetamide,
7 b: (2S) -2- (methylthio) -ethyl-2- (3-benzyl-tert-butylureido) -N-hydroxyacetamide,
8 b: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-benzyl-tert-butylureido) -N-hydroxyacetamide,
1 c: 2- (3-phenethylureido) -N-hydroxyacetamide,
2 c: (2S) -2-methyl-2- (3-phenethylureido) -N-hydroxyacetamide,
3 c: (2S) -2-isopropyl-2- (3-phenethylureido) -N-hydroxyacetamide,
4 c: (2S) -2- (2-methyl) -propyl-2- (3-phenethylureido) -N-hydroxyacetamide,
5 c: (2S) -2- (1-methyl) -propyl-2- (3-phenethylureido) -N-hydroxyacetamide,
6 c: (2S) -2-benzyl-2- (3-phenethylureido) -N-hydroxyacetamide,
7 c: (2S) -2- (methylthio) -ethyl-2- (3-phenethylureido) -N-hydroxyacetamide or
8 c: (2S) -2- [4- (N-benzyloxycarbonyl) -aminobutyl ] -2- (3-phenethylureido) -N-hydroxyacetamide.
3. A process for the preparation of a compound according to claim 1, characterized in that:
optical amino acid is taken as a raw material, carboxyl is protected by methyl esterification in sequence, corresponding amine is connected by triphosgene through condensation, and then the methyl ester is subjected to corresponding reaction to obtain a target compound; or corresponding amine is taken as a raw material, is converted into isocyanate by triphosgene in sequence, is condensed with methyl ester of optical amino acid, and then the methyl ester is subjected to corresponding reaction to obtain a target compound;
the synthetic route is as follows:
wherein R is1、R2A peptoid compound of general formula (i) as defined in claim 1;
reagents in the above reaction scheme: (a) acetyl chloride, anhydrous methanol, reflux (b) triphosgene, saturated aqueous sodium bicarbonate, dichloromethane, various of the above amines used at 0 ℃ (c), triethylamine, dichloromethane (d) potassium hydroxylamine, anhydrous methanol, 25 ℃ (e) triphosgene, toluene, and various of the above amino acid methyl ester hydrochlorides used at reflux (f), triethylamine, dichloromethane.
4. A pharmaceutical composition comprising a compound of claim 1 or 2 and one or more pharmaceutically acceptable carriers or excipients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010146905 CN101817769B (en) | 2010-04-15 | 2010-04-15 | Carbamido peptide aminopeptidase N inhibitor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010146905 CN101817769B (en) | 2010-04-15 | 2010-04-15 | Carbamido peptide aminopeptidase N inhibitor and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101817769A CN101817769A (en) | 2010-09-01 |
CN101817769B true CN101817769B (en) | 2013-09-11 |
Family
ID=42653069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010146905 Expired - Fee Related CN101817769B (en) | 2010-04-15 | 2010-04-15 | Carbamido peptide aminopeptidase N inhibitor and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101817769B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102382014A (en) * | 2011-09-08 | 2012-03-21 | 潍坊博创国际生物医药研究院 | Aminopeptidase N inhibitor, preparation method and application |
CN102850240B (en) * | 2012-10-08 | 2014-02-19 | 成都云克药业有限责任公司 | Preparation method of asymmetric carbamide derivatives |
CN103694139A (en) * | 2013-12-27 | 2014-04-02 | 铁岭选矿药剂有限公司 | Method for synthesizing decyl hydroxamate |
CN104788431B (en) * | 2015-03-26 | 2017-03-22 | 山东大学 | Synthetic method for chiral marine natural product with high optical activity |
CN108218800B (en) * | 2018-02-09 | 2021-01-05 | 山东大学 | 1, 2, 3-triazole aminopeptidase N inhibitor and preparation method and application thereof |
CN109836477B (en) * | 2019-03-19 | 2022-07-12 | 山东大学 | Phenylalanine derivative containing benzothiadiazine-3-ketone 1, 1-dioxide and preparation method and application thereof |
CN114181116B (en) * | 2021-11-22 | 2023-05-23 | 山东中医药大学 | D-amino acid derivative aminopeptidase N inhibitor, and preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0703756D0 (en) * | 2007-02-27 | 2007-04-04 | Surface Therapeutics Ltd | Compounds |
-
2010
- 2010-04-15 CN CN 201010146905 patent/CN101817769B/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
ACS.CAS RN 1091592-42-5.《STN REGISTRY》.2008, * |
Also Published As
Publication number | Publication date |
---|---|
CN101817769A (en) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101817769B (en) | Carbamido peptide aminopeptidase N inhibitor and application thereof | |
JP5921679B2 (en) | Benzylamine derivatives as inhibitors of plasma kallikrein | |
US6528655B1 (en) | Aromatic derivatives with HIV integrase inhibitory properties | |
CN101723896B (en) | Tyrosine derivative histone deacetylases inhibitor and application thereof | |
HU208703B (en) | Process for producing orally administrable elastase inhibitors and pharamceutical compositions containing them | |
JPH08508027A (en) | Natural amino acid derivatives that are inhibitors of metalloproteinases | |
CN112592331B (en) | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | |
CN107118249B (en) | 18 beta-glycyrrhetinic acid derivative and application thereof | |
KR101264934B1 (en) | - 1----- amidomethyl-substituted 1-carboxyalkyl-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives process and intermediate products for their preparation and medicaments containing these compounds | |
TW200407310A (en) | Compounds | |
AU2007242793A1 (en) | Synthesis and uses of pyroglutamic acid derivatives | |
NO178546B (en) | Analogous method for the preparation of therapeutically active ACE inhibitors with nootropic effect | |
KR101055236B1 (en) | Alpha-ketoamide derivatives, and methods of making and using the same | |
CN101357893B (en) | Ethylene diamine metalloid protease inhibitor and use thereof | |
JP7215774B2 (en) | Vestazomib citrate, a multifunctional targeted immune small-molecule anticancer drug, and its preparation and use | |
JPH0741497A (en) | Retroisosteric dipeptide, its production and its use as renin inhibitor in medicine | |
JPH07224091A (en) | New phosphonic acid, its production, and drug composition containing it | |
JP5493870B2 (en) | 3,8-Diaminotetrahydroquinoline derivative | |
CN102276495B (en) | 3-amino-2-hydroxyphenylpropionic acid metalloprotease inhibitor, its preparation and application | |
CN101538311B (en) | Alpha-amido acyl-ring imide peptoid metalloprotease inhibitor and application thereof | |
US6362165B1 (en) | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | |
US20230279052A1 (en) | Prodrugs of mitochondria-targeting oligopeptides | |
CN102010425B (en) | 1,4-disulfide-7-azaspiro [4,4] nonane-8-carboxylic acid derivative histone deacetylase inhibitor and application thereof | |
JP2019522674A (en) | Benzo-N-hydroxyamide compounds having antitumor activity | |
JP2009539904A (en) | Pyrrolidine compounds as renin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130911 Termination date: 20160415 |
|
CF01 | Termination of patent right due to non-payment of annual fee |